Yat Sun Or - 12 Feb 2026 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Reporting relationship: Chief Scientific Officer
Issuer ticker: ENTA
Reported as of: 12 Feb 2026
Net transaction value: -$48,635
SEC form: 4
Accepted by SEC: 13 Feb 2026, 16:27:26 UTC
Prior SEC filing: 05 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Matthew Kowalsky as attorney-in-fact

Key filing fact

Yat Sun Or filed Form 4 for ENANTA PHARMACEUTICALS INC (ENTA) on 13 Feb 2026.

Key facts

This page summarizes Yat Sun Or's Form 4 filing for ENANTA PHARMACEUTICALS INC (ENTA).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 13 Feb 2026, 16:27.

Change

Previous filing in this sequence was filed on 05 Dec 2025.
Current net transaction value: -$48,635.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001571212 Primary reporting owner

Or Yat Sun

Relationship: Chief Scientific Officer
Address: C/O ENANTA PHARMACEUTICALS, INC., 4 KINGSBURY AVENUE, WATERTOWN
Signature: /s/ Matthew Kowalsky as attorney-in-fact
Signature date: 13 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ENTA transaction

Common Stock

Award

Transaction value: $0
Shares: +1,650
Change %: +0.44%
Price: $0.000000
Shares after: 373,042
Date: 12 Feb 2026
Ownership: Direct
Footnotes: F1

ENTA transaction

Common Stock

Award

Transaction value: $0
Shares: +5,225
Change %: +1.4%
Price: $0.000000
Shares after: 378,267
Date: 12 Feb 2026
Ownership: Direct
Footnotes: F2

ENTA transaction

Common Stock

Tax liability

Transaction value: $48,635
Shares: -3,413
Change %: -0.9%
Price: $14.25
Shares after: 374,854
Date: 12 Feb 2026
Ownership: Direct
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026.

Footnote F2

Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026.

Footnote F3

Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.